A new approach to lung cancer treatment uses a tiny metal‑organic framework (MOF) wrapped in lipids to carry the drug anlotinib directly to tumor cells.  

The MOF, called MIL‑101(Fe), is engineered to be very small so it can circulate in the bloodstream without getting trapped in healthy tissues.  

Scientists coat this MOF with a liposome layer, creating a composite called Anlo@MOF‑Lipo (AML).  

The liposome shell shields the drug and helps it fuse with cancer cells, releasing anlotinib where it can inhibit multiple tyrosine kinases involved in tumor growth.  

Preliminary tests show that AML delivers higher drug concentrations to lung tumors while reducing exposure to normal organs.  

This targeted strategy could lower side effects and improve the effectiveness of anlotinib therapy.  

Researchers plan to test AML in animal models next, aiming to confirm its safety and therapeutic benefit before moving toward clinical trials.


# Targeted Lung Cancer Therapy: Anlo@MOF‑Lipo (AML)

**A novel drug delivery system uses a metal‑organic framework (MOF) wrapped in lipids to shuttle the cancer drug anlotinib straight to tumor cells.**

- **MOF Core**: MIL‑101(Fe) – engineered for nanoscale size, enabling it to circulate freely in the bloodstream without lodging in healthy tissues.  
- **Liposome Coating**: Creates a composite called *Anlo@MOF‑Lipo* (AML).  
- **Mechanism**: The liposome shell shields anlotinib and fuses with cancer cells, releasing the drug precisely where it can inhibit multiple tyrosine kinases that drive tumor growth.  

**Key Findings**

- **Higher Tumor Concentration**: Preliminary tests show AML delivers more anlotinib directly to lung tumors.  
- **Reduced Off‑Target Exposure**: Lower drug levels in normal organs suggest fewer side effects.  

**Next Steps**

- Animal model studies are planned to confirm safety and therapeutic benefit before advancing to clinical trials.



Targeted Lung Cancer Delivery Using Tiny Lipid‑Coated MOF Carriers

Actions